Intas Pharmaceuticals has entered into a strategic partnership with IntegriMedical to introduce a needle-free injection system for use in IVF and gynecology treatments, marking a significant step toward patient-friendly reproductive healthcare in India.

With this collaboration, Intas has become the first and only company in the country to offer IVF and gynecology therapies supported by needle-free drug delivery. The initiative is positioned as a major advancement in improving patient comfort and setting new standards for innovation in reproductive medicine.

According to the company, the partnership aims to transform how IVF treatments are experienced by patients, particularly women who undergo repeated hormone injections during therapy. By eliminating needles, the system is expected to reduce pain, anxiety, and overall treatment fatigue, making the process less stressful and more humane.

Intas Executive Vice President Durga P Satapathy said the initiative goes beyond introducing a new technology. He noted that IVF and gynecology treatments can be physically and emotionally demanding, and the company’s objective is to make treatment journeys easier, more reassuring, and dignified for patients.

India is among the fastest-growing IVF markets globally, currently recording an estimated 3 to 5 lakh IVF cycles annually. Market projections suggest this number could rise to 5 to 6 lakh cycles by 2027, underlining the growing need for patient-centric innovations in fertility care.

The Needle-Free Injection System (N-FIS) works by delivering medication through a high-pressure jet stream in a controlled, spray-like pattern. The drug passes through a fine micro-orifice in the skin, ensuring effective delivery without the use of conventional needles. IntegriMedical Managing Director Sarvesh Mutha described the collaboration as a meaningful step toward making treatments more comfortable and less intimidating for patients, emphasizing its potential to improve the IVF experience for hundreds of thousands of women each year.